[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201071291A3 - Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств - Google Patents

Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств

Info

Publication number
EA201071291A3
EA201071291A3 EA201071291A EA201071291A EA201071291A3 EA 201071291 A3 EA201071291 A3 EA 201071291A3 EA 201071291 A EA201071291 A EA 201071291A EA 201071291 A EA201071291 A EA 201071291A EA 201071291 A3 EA201071291 A3 EA 201071291A3
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
disorders
neuropsyatric
receptor antagonists
nmda receptor
Prior art date
Application number
EA201071291A
Other languages
English (en)
Other versions
EA020339B1 (ru
EA201071291A2 (ru
Inventor
Рэймонд Дж. Дингледин
Стефен Ф. Трейнелис
Original Assignee
Эмори Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмори Юниверсити filed Critical Эмори Юниверсити
Publication of EA201071291A2 publication Critical patent/EA201071291A2/ru
Publication of EA201071291A3 publication Critical patent/EA201071291A3/ru
Publication of EA020339B1 publication Critical patent/EA020339B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Представлены фармацевтические композиции и способы для лечения или профилактики некоторых нейропсихиатрических состояний, в частности расстройств эмоционального состояния. Данные соединения отвечают общим формулам I-V, как описано в описании к заявке.
EA201071291A 2008-05-09 2009-05-11 Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств EA020339B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12709808P 2008-05-09 2008-05-09
PCT/US2009/043502 WO2009137843A2 (en) 2008-05-09 2009-05-11 Nmda receptor antagonists for the treatment of neuropsychiatric disorders

Publications (3)

Publication Number Publication Date
EA201071291A2 EA201071291A2 (ru) 2011-04-29
EA201071291A3 true EA201071291A3 (ru) 2014-02-28
EA020339B1 EA020339B1 (ru) 2014-10-30

Family

ID=41265475

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071291A EA020339B1 (ru) 2008-05-09 2009-05-11 Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств

Country Status (16)

Country Link
US (1) US20110160223A1 (ru)
EP (1) EP2296658A4 (ru)
JP (1) JP2011520815A (ru)
KR (1) KR20110016891A (ru)
CN (1) CN102762207A (ru)
AU (1) AU2009244082A1 (ru)
BR (1) BRPI0912362A2 (ru)
CA (1) CA2722776A1 (ru)
CO (1) CO6341558A2 (ru)
EA (1) EA020339B1 (ru)
IL (1) IL208895A0 (ru)
MX (1) MX2010012186A (ru)
NZ (1) NZ589764A (ru)
SG (1) SG195568A1 (ru)
WO (1) WO2009137843A2 (ru)
ZA (1) ZA201007958B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
RS64332B1 (sr) 2011-09-08 2023-08-31 Sage Therapeutics Inc Neuroaktivni steroidi, kompozicije i njihova upotreba
US9951088B2 (en) * 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
US8974365B2 (en) * 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
US20160031930A1 (en) 2013-03-13 2016-02-04 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US20160368897A1 (en) 2013-06-28 2016-12-22 Emory University Pyrazoline Dihydroquinolones, Pharmaceutical Compositions, and Uses
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
MY202135A (en) * 2014-10-07 2024-04-05 Sage Therapeutics Inc Uses of neuroactive compounds
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
MA42410B1 (fr) 2015-07-06 2021-04-30 Sage Therapeutics Inc Oxystérols et leurs méthodes d'utilisation
DK3319612T3 (da) 2015-07-06 2021-08-23 Sage Therapeutics Inc Oxysteroler og fremgansmåder til anvendelse derfor
EP4316591A3 (en) 2015-07-06 2024-04-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2843724T3 (es) 2015-11-30 2021-07-20 Inst Nat Sante Rech Med Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral
WO2017173358A1 (en) 2016-04-01 2017-10-05 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
CN115322238A (zh) 2016-10-18 2022-11-11 萨奇治疗股份有限公司 氧甾醇及其使用方法
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
CN109803656B (zh) * 2017-10-09 2021-08-31 华南农业大学 一种抗白色念珠菌的化合物及其制备方法和应用
WO2019191424A1 (en) 2018-03-28 2019-10-03 Emory University Glun2c/d subunit selective antagonists of the n-methyl-d-aspartate receptor
MX2020012475A (es) 2018-06-27 2021-04-28 Clexio Biosciences Ltd Metodo para tratar el trastorno depresivo mayor.
US11865088B2 (en) 2018-10-05 2024-01-09 Clexio Biosciences Ltd. Method of treating major depressive disorder
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
CN114539129B (zh) * 2020-11-18 2023-06-09 上海中医药大学附属龙华医院 烯丙胺类双功能化合物及其用途
WO2023034589A1 (en) * 2021-09-02 2023-03-09 Emory University Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2824677A1 (de) * 1978-06-06 1979-12-20 Hoechst Ag Neue substituierte phenylpiperazinderivate und verfahren zu deren herstellung
JPS55162774A (en) * 1979-06-06 1980-12-18 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649362A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Thiocarbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS579769A (en) * 1980-06-23 1982-01-19 Otsuka Pharmaceut Co Ltd 2-benzimidazolinone derivative
JPS58203968A (ja) * 1982-05-21 1983-11-28 Otsuka Pharmaceut Co Ltd イソカルボスチリル誘導体
CN85108214A (zh) * 1984-11-22 1986-08-20 赫彻斯特股份公司 新的取代的苯基哌嗪衍生物及其药物的制造方法
JPS62252783A (ja) * 1986-02-13 1987-11-04 ワ−ナ−−ランバ−ト・コンパニ− ベンズ複素環式化合物
GB9005318D0 (en) * 1990-03-09 1990-05-02 Isis Innovation Antiarrhythmic agents
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
DE69828317T2 (de) * 1997-10-31 2005-05-25 Daiichi Suntory Pharma Co., Ltd. Verfahren zur Herstellung von N-((4-Phenyl)methylphenyl)piperazinen
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US7022882B2 (en) * 2000-10-06 2006-04-04 The Regents Of The University Of California NMDA receptor channel blocker with neuroprotective activity
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
JP2005506292A (ja) * 2001-03-08 2005-03-03 エモリー　ユニバーシティ ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
DE10248925A1 (de) * 2002-10-15 2004-04-29 Proteosys Ag Neue Verbindungen mit dopaminerger und/oder serotoninerger Aktivität
BRPI0419067A (pt) * 2003-05-16 2007-12-11 Pfizer Prod Inc método para aumento da cognição utilizando ziprasidona
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
HUP0401526A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet Aryloxy acetic acid amide derivatives, pharmaceutical compositions comprising thereof, methods for their preparation and their use
WO2006023957A1 (en) * 2004-08-23 2006-03-02 Emory University Improved selection of-ph dependent compounds for in vivo therapy
CA2614833A1 (en) * 2005-07-12 2007-01-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 2, 3-disubstituted tropanes for the treatment of disorders of sexual desire
AR055203A1 (es) * 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
US7935706B2 (en) * 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
WO2009006437A1 (en) * 2007-06-29 2009-01-08 Emory University Nmda receptor antagonists for neuroprotection

Also Published As

Publication number Publication date
MX2010012186A (es) 2011-02-22
EA020339B1 (ru) 2014-10-30
JP2011520815A (ja) 2011-07-21
BRPI0912362A2 (pt) 2015-10-06
EP2296658A4 (en) 2014-01-15
NZ589764A (en) 2012-10-26
WO2009137843A9 (en) 2010-03-11
ZA201007958B (en) 2011-07-27
EA201071291A2 (ru) 2011-04-29
CN102762207A (zh) 2012-10-31
WO2009137843A2 (en) 2009-11-12
SG195568A1 (en) 2013-12-30
IL208895A0 (en) 2011-01-31
CA2722776A1 (en) 2009-11-12
AU2009244082A1 (en) 2009-11-12
US20110160223A1 (en) 2011-06-30
KR20110016891A (ko) 2011-02-18
CO6341558A2 (es) 2011-11-21
EP2296658A2 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
EA201071320A1 (ru) Активаторы глюкокиназы
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
GT201400111A (es) Triazolopiridinas sustituidas
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU